ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about a class action lawsuit related to misleading statements made during the company's IPO and subsequent period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Alto securities during the IPO on February 2, 2024, and up until October 22, 2024 [1]. - A lead plaintiff deadline has been set for September 19, 2025, for those wishing to represent the class [1][3]. Group 2: Compensation Information - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 3: Allegations Against Alto Neuroscience - The lawsuit claims that Alto made materially false and misleading statements regarding its product ALTO-100, particularly its effectiveness in treating major depressive disorder (MDD) [5]. - It is alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to inflated business and financial prospects for Alto [5].